·       Research Scholar: University of Southern Cancer Center, Los Angeles, 1977 – 1982

·       Assist Prof of Res Med: USC School of Medicine, 1982 – 1983

·       Clin Assist Prof of Med: USC School of Medicine, 1985 – 1986

·       Assoc Prof Medicine: Medical Oncology, USC School of Medicine, 1986 – 1997

·       Prof Clin Medicine: Medical Oncology, USC School of Medicine, 1997 – 1999

·       Active Staff, Medical Oncology & Hematology, Huntington Memorial Hospital, Pasadena, California,

      1997 – 1999

·       Member, Huntington Medical Research Institute, Pasadena, California, 1996 -1999

·       Research Scholar, USC Department of Chemistry, Los Angeles, CA, 1998 – 2001

·       Senior Clinical Research Physician, Oncology Products, Eli Lilly & Company, Lilly Corporate Center,       Indianapolis, Indiana. 01/04/1999 - 08/04/1999

·       Attending Physician, Woodland Clinic, Woodland, CA, 03/2001 - 12/2001

·       Attending Physician, Sacramento Center of Hematology &Medical Oncology,

      2800 L Street, Sutter Cancer Center, Sacramento, CA. 12/1999 – 03/2001

·       Attending Physician, Sierra Hematology & Oncology,

      Suite 360, 3939 J Street, Sacramento, CA 95819, 03/26/2001 – present

·       Partner, Sierra Hematology & Oncology Medical Centers, 2001 – 2017  Retirement

·       Chairman, Cancer Committee, Mercy General Hospital, Community Comprehensive Cancer Center, Sacramento, 2008 – 2016

·       Chairman, Weekly Tumor Conference, Mercy General Hospital, Sacramento, 2008 – 2014

·       Member, Institutional Review Board, Catholic HealthCare West, Sacramento Region 2001 – 2017

·       Clinical Professor, California Northstate University, College of Medicine 2013 - 2020

Graduate & Post-Graduate Teaching  USC, 1985-1997

1.   Sang-Ihn Kang, Ph.D., 1985-9. Synthetic chemist. Won a National Academy of Sciences National Research Council Fellowship to work with Dr. Kurt Kohn at the National Cancer Institute’s Laboratory of Molecular Pharmacology.

2.   Jashovam Shani, Ph.D., 1984-5. UICC Eleanor Roosevelt Fellow. Appointed Director of the Food and

      Drug Administration of Israel in 1989.

3.   Nitya G. Kundu, Ph.D., Summer, 1988. UICC Traveling Fellowship, from his post as Professor of

     Chemistry, Indian Association for the Cultivation of Science, Calcutta, India.

4.   Andrea H. Hayes, Summer, 1987. Junior, pre-med student. USC research done before entry into

      Dartmouth Medical School.

5.   Shawn Granger, Summer 1988. West Point graduate, USC School of Medicine.

6.   Ph.D. Guidance Committee, Dean of Graduate Studies Representative, Paresh Sanghani, 1996; Elaine

      Chen, 1992 (USC School of Pharmacy);Jingwen (Jenny) Zheng, 1994; Jeff Wang, 1994.

7.   Helena Gustavsson, premedical student, U. of Göteborg, Sweden, 1992-93.

8.   Francisco Bravo H.S. preceptor and Science Fair judge, 1991 -1999.

9.   University of Göteborg M.D./Ph.D. graduate USC studies preceptor for: Magnus Berne, M.D., Ph.D.

     (1986), Roland Frösing, M.D., Ph.D. (1992), Per-Anders Larsson (1994).

CNUCOM, 2014-2019

1.   Aye Khine, 2nd-Yr. Doctoral Candidate, Prolonged Myelosuppression of Bendamustine, and its

      Low Nucleophilic Selectivity.

2.   Sylvia Bowditch, Cristopher Phillips, and Jacob Stoker, 2nd-Yr. Doctoral Candidates

      Barriers to Access  to Care at Chemotherapy Infusion Centers, by Patients with Paraplegia.

 Memberships  Past and Present

·          American Medical Association

·          Sacramento-El Dorado County Medical Association

·          Sierra Sacramento Valley Medical Society

·          Los Angeles County Medical Association

·          Pasadena Medical Society

·          California Medical Association

·          American Association for Cancer Research

·          American Society for Clinical Oncology

·          Association of Northern California Oncologists

·          American Society of Hematology

·          American Chemical Society

·          American Society for Cell Biology - ASCB

·          SPIE-The International Society for Optical Engineering

·          International Union of Pure and Applied Chemistry

·          International Society for the Study of Xenobiotics

·          International Society for the Study of Comparative Oncology

·          Mathematics Association of America

·          American Mathematics Society

·          Fibonacci Association

·          American Statistical Association

·          South Bay Writers Club (California Writers Club)

1.    Spears, C.P., Hyatt, K.H., Vogel, J.M., and Langfitt, S.G. Unified method for serial study of body fluid compartments.
Aerosp. Med., 45:274-278, 1974.

2.    Hyatt, K.H., Johnson, P.C., Hoffler, G.W., Rambaut, P.C., Rummel, J.A., Hulley, S.B., Vogel, J.M., Huntoon, C., and Spears, C.P. Effect of potassium depletion in normal males: an Apollo 15 simulation.
Aviat. Space Environ. Med., 46:11-15, 1975.

3.    Moran, R.G., Spears, C.P., and Heidelberger, C. Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2’-deoxyuridylate, 2’-deoxyuridylate, and thymidylate synthetase.
Proc. Natl. Acad. Sci. USA, 75:1456-1460, 1979.

4.    Spears, C.P. Nucleophilic selectivity ratios of model and clinical alkylating agents by 4-(4’-nitrobenzyl)pyridine product competition.
Mol. Pharmacol., 19:496-504, 1981.

5.    Peterson, A.R., Landolph, J.R., Peterson, H., Spears, C.P., and Heidelberger, C. Oncogenic transformation and mutation of C3H&10T1&2 CL 8 mouse embryo fibroblasts by alkylating agents.
Cancer Res., 41:3095-3099, 1981.

6.    Spears, C.P., Shahinian, A.H., Moran, R.G., Heidelberger, C., and Corbett, T.H. In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sensitive and resistant murine colon adenocarcinomas.
Cancer Res., 42:450-456, 1982.

7.    Spears, C.P. Thymidylate synthetase inhibition in Peyton colon adenocarcinoma xenografts following bolus 5-fluorouracil.
Exerpta Med. Int. Congr. Series 647:12-19, 1984.

8.    Spears, C.P. Volume doubling measurement of spherical and ellipsoidal tumors.
Med. Pediat. Oncol., 12:212-217, 1984.

9.    Spears, C.P., Gustavsson, B.G., Mitchell, M.S., Spicer, D.V., Berne, M., Bernstein, L., and Danenberg, P.V. Thymidylate synthetase inhibition in malignant tissues and normal liver of patients given intravenous 5-fluorouracil.
Cancer Res., 44:4144-4150, 1984.

10.  Spears, C.P., Shani, J., Shahinian, A.H., Wolf, W., Heidelberger, C., and Danenberg, P.V. Assay and time course of 5-fluorouracil incorporation into RNA of L1210&0 ascites cells in vivo.
Mol. Pharmacol., 27:302-307, 1985.

11.  Berne, M.H.O., Gustavsson, B.G., Almersjo, O., Spears, C.P., and Frösing, R. Sequential methotrexate-5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma.
Cancer Chemother. Pharmacol., 16:237-242, 1986.

12.  Berne, M.H.O., Gustavsson, B., Almersjo, O., Spears, C.P., and Waldenstrom, J. Concurrent allopurinol and 5-fluorouracil: 5-fluoro-2’-deoxyuridylate formation and thymidylate synthase inhibition in rat colon carcinoma and in regenerating rat liver.
Cancer Chemother. Pharmacol., 20:193-197, 1987.

13.  Kang, S-I., and Spears, C.P. Linear free energy relationships and cytotoxicities of para!substituted 2-haloethylarylselenides and bis(2-chloroethyl)selenides.
J. Med. Chem., 30:597-602, 1987.

14.  Kang, S-I., and Spears, C.P. A facile synthesis of 2- and 3-hydroxyalkylseleno compounds.
Synthesis, 133-135, 1988.

15.  Spears, C.P., and Gustavsson, B.G. Methods for thymidylate synthase pharmacodynamics: Serial Biopsy, free and total TS, FdUMP and dUMP, and H4PteGlu and CH2-H4PteGlu assays.
Adv. Exp. Med. Biol. 244: 97-106, 1988.

16.  Gustavsson, B.G., Carlsson, G., Frösing, R., and Spears, C.P. Pharmacodynamics of fluorouracil and leucovorin.
Adv. Exp. Med. Biol. 244: 219-224, 1988.

17.  Berne, M., Gustavsson, B., Almersjo, O., Spears, C.P., and Sundstrom, E. Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat.
Cancer Invest., 6:377-384, 1988.

18.  Spears, C.P., Gustavsson, B.G., Berne, M., Frösing, R., and Hayes, A.A. Mechanisms of innate resistance to thymidylate synthase inhibition after fluorouracil.
Cancer Res., 48:5894-5900, 1988.

19.  Peterson, A.R., Peterson, H., Spears, C.P., Trosko, J.E., and Sevanian, A. Mutagenic characterization of cholesterol epoxides in Chinese hamster V79 cells.
Mut. Res., 203:355-366, 1988.

20.  Spears, C.P., Gustavsson, B.G., and Frösing, R. Folinic acid modulation of fluorouracil: kinetics of bolus administration.
Invest. New Drugs, 7:27-36, 1989.

21.  Spears, C.P., Hayes, A.H., Danenberg, P.V., Shahinian, A., Frösing, R., and Gustavsson, B.G. Deoxyuridylate effects on thymidylate synthase-5-fluorodeoxyuridylate-folate ternary complex formation.
Biochem. Pharmacol., 38:2985-2993, 1989.

22.  Buzaid, A.C., Alberts, D.S., Einspahr, J., Mosley, K., Peng, Y-M., Garewal, H.S., Tutsch, K., and Spears, C.P. Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients.
Cancer Chemother. Pharmacol., 25:124-130, 1989.

23.  Kang, S-I., and Spears, C.P. Structure-activity studies on organoselenium alkylating agents.
J. Pharm Sci., 79:57-62, 1990.

24.  Leichman, C.G., Leichman, L., Spears, C.P., Rosen, P., Muggia, F.M., Jeffers, S., and Waugh, W. Biological modification of protracted infusion of 5-fluorouracil with weekly leucovorin. A dose seeking clinical trial for patients with disseminated gastrointestinal cancers.
Cancer Chemother. Pharmacol., 26:57-61, 1990.

25.  Kang, S-I., and Spears, C.P. Phenyl selenones: alkyl transfer by selenium-carbon bond-cleavage.
J. Med. Chem., 33:1544-1547, 1990.

26.  Kundu, N.G., Das, B., Spears, C.P., Mazumder, A., and Kang, S-I. Synthesis and biological activities of novel 5-(2-acylethynyl)uracils.
J. Med. Chem., 33:1975-1979, 1990.

27.  Carlsson, G., Gustavsson, B.G., Spears, C.P., and Hofström, L-O. 5-Fluorouracil plus leucovorin as adjuvant therapy of an experimental liver tumor in rats.
Anticancer Res., 10:813-816, 1990.

28.  Carlsson, G., Gustavsson, B.G., Glimelius, B., Graf, W., Påhlman, L., and Spears, C.P. Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer.
Eur. J. Cancer, 26:874-876, 1990.

29.  Horikoshi, T., Danenberg, K.D., Stadlbauer, T.H.W., Volkenandt, M., Shea, L.C.C., Aigner, K., Gustavsson, B.G., Leichman, L., Frösing, R., Ray, M., Gibson, N.W., Spears, C.P., and Danenberg, P.V. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT!diaphorase gene expression in human tumors using the polymerase chain reaction.
Cancer Res., 52:108-116, 1992.

30.  Leichman, L., Silberman, H., Leichman, C.G., Spears, C.P., et al. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program.
J. Clin. Oncol., 10:1933-1942, 1992.

31.  Leichman, C.G., Leichman, L., Spears, C.P., Rosen, P.J., Jeffers, S., and Groshen, S. Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer.
J. Natl. Cancer Inst., 85:41-44, 1993.

32.  Hoier, H., Carrell, H.L., Glusker, J.P., and Spears, C.P. Structure of ethyl phenylselenone.
Acta Crystallogr., 49:520-523, 1993.

33.  Kundu, N.G., Dasgupta, S.K., Chadhuri, L.N., Mahanty, J.S., Spears, C.P., and Shahinian, A.H. Synthesis and biological activities of 5-(2-acylvinyl) uracils.
Eur. J. Med. Chem., 28:473-479, 1993.

34.  Carlsson, G., Hofström, L-O., Spears, C.P., and Gustavsson, B.G. Sequential 5-fluorouracil and leucovorin. An experimental study in rats with hepatic metastasis of a rat colon carcinoma: clinical relevance for scheduling.
Reg. Cancer Treat., 3:140-143, 1993.

35.  Muggia, F.M., Tulpule, A., Retzios, A., Chen, F., Jeffers, S., Leichman, C.G., Leichman, L., Spears, C.P., and Chan, K.K. Intraperitoneal 5-fluoro-2’-deoxyuridine with escalating doses of leucovorin: pharmacology and clinical tolerance.
Invest. New Drugs, 12:197-206, 1994.

36.  Spears, C.P. Clinical resistance to antimetabolites.
Hematol./Oncol. Clin. N. Amer., 9:397-413, 1995.

37.  Carlsson, G., Larsson, P-A., Frösing, R., Hafström, L-O., Spears, C.P., Peterson, A., and Gustavsson, B. 5-Fluorouracil sensitive adenocarcinoma - A new experimental model in the rat.
Anticancer Res., 15:433-440, 1995.

38.  Kundu, N.G., Mahanty, J.S., Spears, C.P., Andrei, G., Snoek, R., Balzarini, J., and DeClercq, E. Palladium-catalyzed synthesis of [E]-5-(2-acylvinyl)-2’-deoxyuridines and their biological activities.
Bioorg. Medicinal Chem. Lett., 5:1627-1632, 1995.

39.  Leichman, L., Lenz, H-J., Leichman, C.G., Groshen, S., Danenberg, K., Baranda, J., Spears, C.P., Boswell, W., Silberman, H., Ortega, A., Stain, S., Beart, R., and Danenberg, P. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial.
Eur. J. Cancer, 31A:1306-1310, 1995.

40.  Larsson, P-A., Carlsson, G., Gustavsson, B., Hafström, L-O., Peterson, A., and Spears, C.P. Effects of 5,10-methylene-tetrahydrofolate on rat colon tumour growth and biomodulation of 5-fluorouracil.
Reg. Cancer Treat., 8:101-108, 1995.

41.  Banerjee, D., Lenz, H-J., Schnieders, B., Manno, D.J., Ju, J.F., Spears, C.P., Hochhauser, D., Danenberg, K., Danenberg, P., and Bertino, J.R. Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress.
Cell Growth & Differ., 6:1405-1413, 1995.

42.  Carlsson, G., Gustavsson, B., Frösing, R., Odin, E., Hafström, L-O., Spears, C.P., and Larsson, P-A. Antitumour effects of pure diastereoisomers of 5-formyltetrahydrofolate in hepatic transplants of a rodent colon carcinoma model.
Biochem. Pharmacol., 50:1347-1351, 1995.

43.  Kundu, N.G., Mahanty, J.S., Spears, C.P., Andrei, G., Snoeck, R., Balzarini, J.,DeClerque,E., Palladium-catalyzed synthesis of (E)-5-(2-acylvinyl)-2'-deoxyuridines and their antiviral and cytotoxic activities.
Bioorg. Med. Chem. Lett. 5:1627-1632, 1995.

44.  Spears, C.P., Carlsson, G., Muggia, F.M., Waugh, W., Jaresko, G., and Gustavsson, B.G. Aspects of one-carbon folate cycling related to fluoropyrimidine and antifolate therapy.
Cancer Treat. Res. 78: 115-134, 1995.

45.  Bicknell-Johnson, M., and Spears, C.P. Classes of identities for the generalized Fibonacci numbers Gn = Gn-1 + Gn-c from matrices with constant valued determinants.
Fibonacci Quarterly 34.3:121-128, 1996.

46.  Larsson, P.-A., Carlsson, G., Gustavsson, B, and Spears, C.P. Thymidylate synthase in advanced gastrointestinal and breast cancers.
Acta Oncol. 35:469-472,1996.

47.  Kundu, N.G., Mahanty, J.S., Unusual cytotoxicities of 5-(acylethynyl)-1-(2-hydroxy-ethoxy)methyl uracils.
Bioorg. Med. Chem. Lett. 6:1497-1502, 1996.

48.  Das, P., Spears, C.P., Shahinian, A.H., Dasgupta, S.K., and Kundu, N.G. Palladium-catalyzed synthesis of some biologically-active 5,6-disubstituted uracils.
Biorg. Med. Chem. Lett. 6: 2477-2480, 1996.

49.  Quan, W.D.Y., Jr., Dean, G.E., Spears, L., Spears, C.P., Groshen, S., Merritt, J.A., and Mitchell, M.A. Active Specific Immunotherapy of Metastatic Melanoma with Anti-Idiotype Vaccine: A Phase I/II Trial of I-Mel-2 Plus SAF-m.
J. Clin. Oncol. 15: 2103-2110, 1997.

50.  Carlsson, G., Odin, E., P-A. Larsson, Frösing, R., Spears, C.P., and Gustavsson, B., Phase I-II study of weekly 5-fluorouracil and 5,10-methylene-tetrahydrofolate in patients with advanced gastrointestinal and breast cancer
Cancer J. 10: 266-273, 1997.

51.  Frösing, R., Gustavsson, B., Carlsson, G., Larsson, P-A., Odin, E., and Spears, C.P. Decreases in FdUMP ligand-binding sites in normal liver and adenocarcinoma in patients receiving various folates.
Reg. Cancer Treat., 1997.

52.  Odin, E., Carlsson, G., Frösing, R., Gustavsson, B., Spears, C.P., and Larsson, P.A. Chemical stability and human plasma pharmacokinetics of reduced folates.
Cancer Invest. 16(7):447-455, 1998.

53.  Spears,C.P., S-I Kang, N.G. Kundu, T. Shamma, and G.A. Olah. Swain-Scott constants and alkylating agent drug design.
Current Topics Medicinal Chem. 2:85-100, 1997.

54.  Carlsson, G., Hafström, L-O, and Spears, C.P., Gustavsson, B., and Larsson, P.A 5-Fluorouracil (5-FU) and 5,10-methylene tetrahydrofolate (CH2FH4) as adjuvant therapy in an experimental colon carcinoma in rats.
Anticancer Res.17(5A):3671-3674, 1997.

55.  Yang, L., Chiang, Y., Lenz, H.J., Danenberg, K.D., Spears, C,P., Gordon, E.M., Anderson, W.F., and Parekh, D. Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells.
Hum. Gene Ther. 9:719-728, 1998.

56.  Spears, C.P., and Bicknell-Johnson, M. Asymmetric cell division: Binomial identities for age analysis of mortal and immortal trees.
Fibonacci Numbers and their Applications 7: 377-391, 1998.

57.   Ju, J.F., Banerjee, D., Lenz, H.J., Danenberg, K.D., Schmittgen, T.C., Spears, C.P., Schonthal, A.H., Manno, D.J., Hochhauser, D., Bertino, J.R., and Danenberg, P.V. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity.
Clin. Cancer Res. 4(5):1315-1322, 1998.

58.  Kundu, N.G., Mahanty, J.S., Chowdhury, C., Dasgupta, S.K., Das, B., Spears, C.P., Balzarini, J., and De Clerq, E. 5-(Acylethynyl)uracils, 5-(acylethynyl)-2'-deoxyuridines and 5-(acylethynyl)-1-(2-hydroxyethoxy)methyluracils. Their synthesis, antiviral and cytotoxic activities.
Eur. J. Medicinal Chem. 34(5):389-398, 1999.

59.  Williams-Hill, D.M., Spears, C.P., Parkash, S., Olah, G.A., Shamma, T., Moin, T., Kim, L.Y.,and Hill, C.K. Mutagenicity studies of methy-tert-butyl ether (MTBE) using the Ames tester strain TA102
Mutation Res. 446:15-21, 1999.

60.  Yazan, O., Spears, C.P., Carlsson, G., Gustavsson, B., Ingram, M.L., and Gruia, G. Thymidylate Synthase (TS) and Ki-67 expression in tumor cells of patients with advanced colon cancer randomized to irinotecan (CPT-11) vs. 5-fluorouracil (5-FU). Annals of Oncology (11):54, 2000.

61.  Garcia, A.A, Muggia, F.M., Spears, C.P., Jeffers, S., Silberman, H., Pujari, M., Koda, R.T. Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2’-deoxyuridine and leucovorin.
Anticancer Drugs 12(6):505-511, 2001.

62.  Odin, E., Wettergren, Y., Nilsson, S., Willen, R., Carlsson, G., Spears, C.P., and Gustavsson, B. Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients.
Clin. Cancer Res. 9(16):6012-6019, 2004.

63.  Spears, C.P., Bicknell-Johnson, M., and Yan, J.J. Fibonacci Phyllotaxis by Asymmetric Cell Division: Zeckendorf and Wythoff Trees.
Congressus Numerantium 201: 257-272, 2009.

64.  Bicknell-Johnson, M. and Spears, C.P. Lucas Quotient Lemmas.
Congressus Numerantium 201: 273-275, 2009.

65.  Bicknell-Johnson, M. and Spears, C.P. Hexahexaflexagons: a Mathematical Ramble.
Aportaciones Matimaticas Investigation 20: 61-70, 2011. \

66.  Bicknell-Johnson, M. and Spears, C.P. The Golden Ratio in Classical Maya Architecture.
Proceedings of the Fifteenth International Conference on Fibonacci Numbers and their Applications, Eszterhay College, Eger, Hungary, June 26, 2012.

67.   Verstovsek S, Mersa RA, Gotlib J, … Spears, C.P et al. Efficacy, Safety, and Survival with Ruxolitinib in Patients with Myelofibrosis: Results of a Median 3 - years follow up of COMFORT-I. Haematologica. 
2015 Apr;100(4):479-88.

68.  Vannucchi AM, Kantarjian HM, Kiladjian JJ, …Spears C.P et al. A Pooled Analysis of Overall Survival in COMFORT-I and COMFORT-II, 2 Randomized Phase III Trials of Ruxolitinib for the Treatment of Myelofibrosis. Haematologica. 2015 Sep;100(9): 1139-45.

1. Spears, C.P. Thymidylate synthetase inhibition in Peyton adenocarcinoma xenografts following bolus

5-fluorouracil. Exerpta Med. Int. Congr. Series, 647:12-19, 1984.

2. Spears, C.P. Management of the Patient with Paraneoplasia. Hospital of the Good Samaritan Manual, Hematology-Oncology Unit, 1984, pp. 1-118.

3. Spears, C.P., Ray, M., Granger, S., Diasio, R.B., and Gustavsson, B.G. Dual role of serine hydroxymethyltransferase in the synergy of fluorouracil and leucovorin: effects of L-serine and glycine on H4PteGlu/5,10-CH2-H4PteGlu ratios; and H4PteGlu-catalyzed release of fluoride ion from alpha!fluoro!beta-alanine. IN: Pteridines and Folic Acid Derivatives (H.Ch. Curtius, S. Ghisla and N. Blau, eds.), Walter de Gruyter, Berlin, 1990.

4. Alaverdian, A., Spears, C.P., Kang, S-I., and Shahinian, A.H. High nitrogen and low sulfur selectivities of alkyl aryl selenones and activities against drug!resistant tumor cell lines. USC Undergrad. J., 2: (1992).

5. Spears, C.P., and Danenberg, P.V. Thymidylate synthase pharmacodynamics; Minutes of the NCI Phase

I Working Group, NCI, CTEP, DCT. Bethesda, MD, October 27 and 28, pp 87-109, 1993.

6. Spears, C. P., Thyroid Cancer, IN: The Complete Cancer Survival Guide, by P. Teely and P. Bashe, Doubleday Books, May, 2000.

7.  Spears, C. P.  Writers Block and A Song of Fertility. Poems in: Writers Talk, Monthly Newsletter of South Bay Writers Club. 21(6):10,11, 2014.

8. Spears, C.P. Parallel, and Our. Poems in: Writers Talk, Monthly Newsletter of South Bay Club 22 (4): 11, 2014.

9. Spears, C. P. Photo credit. Dedication to Herta Taussig Freitag, Fibonacci Quarterly 34 (5): 467, 1996.

10. Hyatt, K.H., Sullivan, R.W., Spears, C.P., and Vetter W.R. A Study of ventricular contractility and other parameters possibly related to vasodepressor syncope.

     US Public Health Service Hospital, San Francisco. NASA CR T-81035, pp.1-35, 1973.

1. Spears, C.P. Tumor Growth Measurement Device.

U.S. Patent 4,131,998. Jan 2, 1979.

2. Spears, C.P. Biopsy Retriever.

U.S. Patent 5, 133, 360. July 28, 1992.

3. Spears, C.P., and Gustavsson, B.G. Use of 5,10-Methylene-tetrahydrofolate as a Modulator of a

Chemotherapeutic Agent.

U.S. Patent 5, 376,650. December 27, 1994.

4. Spears, C.P., and Gustavsson, B.G. Use of 5,10-Methylene-tetrahydrofolate as a Modulator of a

Chemotherapeutic Agent (Continuation in Part) U.S. Patent 5,534,519. July 9, 1996.

5. Spears, C.P., and Kang, S!I. 2-Chloroethyl Aryl Selenones against Alkylating Agent Resistant Cancer

Cells.

U.S. Patent 5,614,562. March 25, 1997.

6. Spears, C.P., Gustavsson, G., and Carlsson, G. 5,10-Methylene-tetrahydrofolate as a Modulator of a

Chemotherapeutic Agent,

Canadian Patent Application 2,082,881, Notice of Allowance March 16, 2004.

7. Spears, C.P. and Brower, S.P. System and Method for Evaluating Tumor Stability, U.S.Patent,

      17/167,830. Filed 02/04/2021.

8. Spears, C.P. and Brower, S.P. Transparent Tumor Size Measuring Ruler. US Design Patent

      Application 29833158. April1, 2022.

1.    Heidelberger, C., and Spears, C.P. Determinants of sensitivity to 5-fluorouracil (5-FU): new ultrasensitive assays for 5-fluorodeoxyuridylate (FdUMP), deoxyuridylate (dUMP), and thymidylate synthetase (TS).

 Proc. Am. Assoc. Cancer Res., 20:63, 1979.

2.    Spears, C.P., Shahinian, A.H., and Heidelberger, C. Relationship between 5-fluorouracil (5-FU) chemotherapeutic efficacy and thymidylate synthetase (TS) inhibition in murine colon carcinomas.